JP2019501962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501962A5 JP2019501962A5 JP2018549135A JP2018549135A JP2019501962A5 JP 2019501962 A5 JP2019501962 A5 JP 2019501962A5 JP 2018549135 A JP2018549135 A JP 2018549135A JP 2018549135 A JP2018549135 A JP 2018549135A JP 2019501962 A5 JP2019501962 A5 JP 2019501962A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- cancer
- dose
- present
- hydroxocobalamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 18
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 claims 18
- 229960005070 ascorbic acid Drugs 0.000 claims 9
- 235000010323 ascorbic acid Nutrition 0.000 claims 9
- 239000011668 ascorbic acid Substances 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 229960001103 hydroxocobalamin Drugs 0.000 claims 9
- 235000004867 hydroxocobalamin Nutrition 0.000 claims 9
- 239000011704 hydroxocobalamin Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 7
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 6
- 229960001924 melphalan Drugs 0.000 claims 6
- 208000037819 metastatic cancer Diseases 0.000 claims 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108700020462 BRCA2 Proteins 0.000 claims 3
- 102000052609 BRCA2 Human genes 0.000 claims 3
- 101150008921 Brca2 gene Proteins 0.000 claims 3
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 claims 3
- 102100034553 Fanconi anemia group J protein Human genes 0.000 claims 3
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 claims 3
- 101000702606 Homo sapiens Structure-specific endonuclease subunit SLX4 Proteins 0.000 claims 3
- 101000837581 Homo sapiens Ubiquitin-conjugating enzyme E2 T Proteins 0.000 claims 3
- 102100031003 Structure-specific endonuclease subunit SLX4 Human genes 0.000 claims 3
- 102100028705 Ubiquitin-conjugating enzyme E2 T Human genes 0.000 claims 3
- 210000004602 germ cell Anatomy 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 108700020463 BRCA1 Proteins 0.000 claims 2
- 101150072950 BRCA1 gene Proteins 0.000 claims 2
- 239000012623 DNA damaging agent Substances 0.000 claims 2
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 claims 2
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- -1 FANJ Proteins 0.000 claims 2
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims 2
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims 2
- 201000000140 Fanconi anemia complementation group T Diseases 0.000 claims 2
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims 1
- 101700002522 BARD1 Proteins 0.000 claims 1
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 claims 1
- 102100035631 Bloom syndrome protein Human genes 0.000 claims 1
- 108091009167 Bloom syndrome protein Proteins 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102100033832 Crossover junction endonuclease EME1 Human genes 0.000 claims 1
- 102100027041 Crossover junction endonuclease MUS81 Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims 1
- 230000033616 DNA repair Effects 0.000 claims 1
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims 1
- 102100022928 DNA repair protein RAD51 homolog 1 Human genes 0.000 claims 1
- 102100034483 DNA repair protein RAD51 homolog 4 Human genes 0.000 claims 1
- 102100028285 DNA repair protein REV1 Human genes 0.000 claims 1
- 102100027830 DNA repair protein XRCC2 Human genes 0.000 claims 1
- 102100027829 DNA repair protein XRCC3 Human genes 0.000 claims 1
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 claims 1
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims 1
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 claims 1
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 claims 1
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 claims 1
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 claims 1
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 claims 1
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 claims 1
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 claims 1
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 claims 1
- 201000000094 Fanconi anemia complementation group R Diseases 0.000 claims 1
- 102100027285 Fanconi anemia group B protein Human genes 0.000 claims 1
- 102100034552 Fanconi anemia group M protein Human genes 0.000 claims 1
- 102100027284 Fanconi-associated nuclease 1 Human genes 0.000 claims 1
- 229940122247 Glutathione reductase inhibitor Drugs 0.000 claims 1
- 102100022536 Helicase POLQ-like Human genes 0.000 claims 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 claims 1
- 101000934870 Homo sapiens Breast cancer type 1 susceptibility protein Proteins 0.000 claims 1
- 101000925818 Homo sapiens Crossover junction endonuclease EME1 Proteins 0.000 claims 1
- 101000982890 Homo sapiens Crossover junction endonuclease MUS81 Proteins 0.000 claims 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims 1
- 101000770953 Homo sapiens DNA repair endonuclease XPF Proteins 0.000 claims 1
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims 1
- 101000620735 Homo sapiens DNA repair protein RAD51 homolog 1 Proteins 0.000 claims 1
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims 1
- 101001132266 Homo sapiens DNA repair protein RAD51 homolog 4 Proteins 0.000 claims 1
- 101000649306 Homo sapiens DNA repair protein XRCC2 Proteins 0.000 claims 1
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 claims 1
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 claims 1
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 claims 1
- 101000914689 Homo sapiens Fanconi-associated nuclease 1 Proteins 0.000 claims 1
- 101000899334 Homo sapiens Helicase POLQ-like Proteins 0.000 claims 1
- 101000582631 Homo sapiens Menin Proteins 0.000 claims 1
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims 1
- 101000894871 Homo sapiens Transcription regulator protein BACH1 Proteins 0.000 claims 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 claims 1
- 101000814276 Homo sapiens WD repeat-containing protein 48 Proteins 0.000 claims 1
- 102100030550 Menin Human genes 0.000 claims 1
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 claims 1
- 102100024403 Nibrin Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101000770949 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) 3'-flap repair endonuclease Xpf Proteins 0.000 claims 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 claims 1
- 102100039414 WD repeat-containing protein 48 Human genes 0.000 claims 1
- 108010074310 X-ray repair cross complementing protein 3 Proteins 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108010073629 xeroderma pigmentosum group F protein Proteins 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263880P | 2015-12-07 | 2015-12-07 | |
| US62/263,880 | 2015-12-07 | ||
| PCT/US2016/065079 WO2017100162A1 (en) | 2015-12-07 | 2016-12-06 | Combination for the effective treatment of metastatic cancer in patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021013001A Division JP7144554B2 (ja) | 2015-12-07 | 2021-01-29 | 患者における転移性癌の有効な治療のための組合せ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501962A JP2019501962A (ja) | 2019-01-24 |
| JP2019501962A5 true JP2019501962A5 (https=) | 2020-01-16 |
| JP6831853B2 JP6831853B2 (ja) | 2021-02-17 |
Family
ID=57708742
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549135A Active JP6831853B2 (ja) | 2015-12-07 | 2016-12-06 | 患者における転移性癌の有効な治療のための組合せ |
| JP2021013001A Active JP7144554B2 (ja) | 2015-12-07 | 2021-01-29 | 患者における転移性癌の有効な治療のための組合せ |
| JP2022147352A Pending JP2022171816A (ja) | 2015-12-07 | 2022-09-15 | 患者における転移性癌の有効な治療のための組合せ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021013001A Active JP7144554B2 (ja) | 2015-12-07 | 2021-01-29 | 患者における転移性癌の有効な治療のための組合せ |
| JP2022147352A Pending JP2022171816A (ja) | 2015-12-07 | 2022-09-15 | 患者における転移性癌の有効な治療のための組合せ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11154520B2 (https=) |
| EP (1) | EP3386546B1 (https=) |
| JP (3) | JP6831853B2 (https=) |
| KR (1) | KR20180086257A (https=) |
| AU (2) | AU2016367112B2 (https=) |
| CA (1) | CA3044959C (https=) |
| DK (1) | DK3386546T3 (https=) |
| ES (1) | ES2994931T3 (https=) |
| FI (1) | FI3386546T3 (https=) |
| HU (1) | HUE069668T2 (https=) |
| IL (2) | IL290251B2 (https=) |
| PL (1) | PL3386546T3 (https=) |
| PT (1) | PT3386546T (https=) |
| WO (1) | WO2017100162A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3388060A1 (en) | 2012-10-22 | 2018-10-17 | Arnold Glazier | Methods for the effective treatment of metastatic cancer |
| WO2017214140A1 (en) * | 2016-06-06 | 2017-12-14 | University Of Iowa Research Foundation | Compositions and methods for cancer therapy |
| EA202190580A1 (ru) | 2018-08-21 | 2021-06-25 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Системз | Композиции и способы для лечения злокачественных клеток посредством индукции цитотоксического оксидативного стресса |
| CN114904011B (zh) * | 2021-07-06 | 2023-10-13 | 中国科学院上海硅酸盐研究所 | 非铁基谷胱甘肽消耗协同活性氧物种增强复合材料及其制备方法和应用 |
| EP4376822A4 (en) * | 2021-07-29 | 2025-09-17 | Lantern Pharma Inc | TREATMENT OF CANCER WITH COMBINATIONS OF PARP INHIBITORS AND ACYLFULVENS |
| CN116407557A (zh) * | 2023-05-29 | 2023-07-11 | 四川大学华西医院 | 一种防治出血性脑卒中的药物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1305873C (en) * | 1987-05-26 | 1992-08-04 | Howel Gwynne Giles | Method and means for detecting alcohol levels in humans |
| US5639787A (en) | 1995-02-28 | 1997-06-17 | The Center For The Improvement Of Human Functioning Int'l, Inc. | Therapeutic method for the treatment of cancer |
| WO2000076556A2 (en) | 1999-06-11 | 2000-12-21 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| EP1313508B1 (en) * | 2000-06-30 | 2007-04-18 | Eli Lilly And Company | Combination containing an antifolate and methylmalonic acid lowering agent |
| EP1485720B1 (en) * | 2002-03-22 | 2008-03-12 | Ludwig Maximilians Universität | Cytocapacity test |
| ES2421516T3 (es) | 2002-11-06 | 2013-09-03 | Dana Farber Cancer Inst Inc | Composiciones para tratar el cáncer usando el inhibidor de proteasomas PS-341 |
| US20090123447A1 (en) * | 2007-11-14 | 2009-05-14 | The Regents Of The University Of California | Compositions and methods to inhibit rna viral reproduction |
| US9050265B2 (en) * | 2009-07-20 | 2015-06-09 | Summa Health System | Vitamin C and vitamin K, and compositions thereof for treatment of osteolysis or prolongation of prosthetic implant |
| EP3388060A1 (en) * | 2012-10-22 | 2018-10-17 | Arnold Glazier | Methods for the effective treatment of metastatic cancer |
-
2016
- 2016-12-06 EP EP16820404.8A patent/EP3386546B1/en active Active
- 2016-12-06 PT PT168204048T patent/PT3386546T/pt unknown
- 2016-12-06 FI FIEP16820404.8T patent/FI3386546T3/fi active
- 2016-12-06 HU HUE16820404A patent/HUE069668T2/hu unknown
- 2016-12-06 US US15/778,796 patent/US11154520B2/en active Active
- 2016-12-06 WO PCT/US2016/065079 patent/WO2017100162A1/en not_active Ceased
- 2016-12-06 CA CA3044959A patent/CA3044959C/en active Active
- 2016-12-06 ES ES16820404T patent/ES2994931T3/es active Active
- 2016-12-06 KR KR1020187019041A patent/KR20180086257A/ko not_active Ceased
- 2016-12-06 AU AU2016367112A patent/AU2016367112B2/en active Active
- 2016-12-06 IL IL290251A patent/IL290251B2/en unknown
- 2016-12-06 JP JP2018549135A patent/JP6831853B2/ja active Active
- 2016-12-06 IL IL259512A patent/IL259512B2/en unknown
- 2016-12-06 DK DK16820404.8T patent/DK3386546T3/da active
- 2016-12-06 PL PL16820404.8T patent/PL3386546T3/pl unknown
-
2021
- 2021-01-29 JP JP2021013001A patent/JP7144554B2/ja active Active
- 2021-10-13 US US17/500,169 patent/US20220096405A1/en not_active Abandoned
-
2022
- 2022-01-11 AU AU2022200131A patent/AU2022200131A1/en not_active Abandoned
- 2022-09-15 JP JP2022147352A patent/JP2022171816A/ja active Pending
-
2024
- 2024-01-09 US US18/408,066 patent/US20240216308A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501962A5 (https=) | ||
| Jiang et al. | Application of CRISPR/Cas9 gene editing technique in the study of cancer treatment | |
| JP2022500435A5 (https=) | ||
| US11976334B2 (en) | Inhibitor of ATR kinase for use in a method of treating a hyper-proliferative disease | |
| Nickoloff et al. | Translational research in radiation-induced DNA damage signaling and repair | |
| CN115279376A (zh) | 用于治疗异常细胞生长的组合疗法 | |
| EP3148336B1 (en) | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer | |
| FI3386546T3 (fi) | Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla | |
| M Rosen et al. | Targeting the BRCA1/2 tumor suppressors | |
| US20190375732A1 (en) | Anti-cancer nuclear hormone receptor-targeting compounds | |
| JP2017516784A5 (https=) | ||
| JP2020516693A5 (https=) | ||
| KR20240121720A (ko) | 메닌-mll 후성유전학적 복합체 파괴에 의한 위장관 기질 종양(gist)의 치료 표적화 | |
| US20210023077A1 (en) | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor | |
| US20200157638A1 (en) | Biomarkers and patient selection strategies | |
| CN115998872B (zh) | 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途 | |
| EP3981430A1 (en) | Methods and compositions for increasing susceptibility to radiation treatment by inhibiting suppression of numerical chromosomal instability of cancer cells | |
| JP2021501203A (ja) | がん治療用のアリールイミダゾール | |
| Shishido et al. | Epigenetic regulation of radioresistance: insights from preclinical and clinical studies | |
| Kaiser et al. | Hypusinated EIF5A as a feasible drug target for Advanced Medicinal Therapies in the treatment of pathogenic parasites and therapy-resistant tumors | |
| US20190365745A1 (en) | Use of chronic treatment with atr inhibitors to sensitize cancer cells to parp inhibitors | |
| CN103491977A (zh) | 癌症的组合治疗 | |
| CN106692155A (zh) | 一种靶向于fen1的小分子抑制剂sc13及其衍生物在制备治疗肿瘤药物中的应用 | |
| ES2898072T3 (es) | Métodos para tratar el cáncer de ovario | |
| Maurya et al. | Challenges and recent advances of novel chemical inhibitors in medulloblastoma therapy |